Banco Bilbao Vizcaya Argentaria S.A. Purchases 29,178 Shares of Illumina, Inc. (NASDAQ:ILMN)

Banco Bilbao Vizcaya Argentaria S.A. grew its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 156.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,865 shares of the life sciences company's stock after purchasing an additional 29,178 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Illumina were worth $6,393,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. Capital World Investors lifted its holdings in shares of Illumina by 408.6% during the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares during the period. WCM Investment Management LLC lifted its stake in shares of Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after buying an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock valued at $454,617,000 after purchasing an additional 27,618 shares in the last quarter. Norges Bank acquired a new position in shares of Illumina during the 4th quarter valued at about $228,714,000. Finally, Bessemer Group Inc. raised its position in shares of Illumina by 32,837.5% during the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after buying an additional 1,344,038 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Down 0.1 %

Shares of ILMN traded down $0.09 during trading hours on Wednesday, hitting $77.01. 835,804 shares of the company were exchanged, compared to its average volume of 2,278,673. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company has a market cap of $12.19 billion, a PE ratio of -10.03, a PEG ratio of 1.60 and a beta of 1.38. The firm's 50 day moving average is $81.11 and its 200-day moving average is $117.11.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several research analyst reports. Piper Sandler raised their price target on Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Stephens restated an "overweight" rating and set a $156.00 target price on shares of Illumina in a research note on Tuesday, March 11th. Robert W. Baird decreased their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. Morgan Stanley lowered their price objective on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. Finally, Hsbc Global Res downgraded Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $137.55.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.